Drugs and patents in ATC class G02CC - Antiinflammatory products for vaginal administration

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ACETAMINOPHEN AND IBUPROFEN	acetaminophen; ibuprofen
ADVIL DUAL ACTION WITH ACETAMINOPHEN	acetaminophen; ibuprofen
COMBOGESIC	acetaminophen; ibuprofen
>Tradename	>Generic Name

Last updated: June 4, 2026

Executive summary: ATC Class G02CC sits in a fragmented, product-specific patent landscape dominated by branded vaginal anti-inflammatories (typically corticosteroid and anti-infective/anti-inflammatory combinations), with exclusivity driven by (i) formulation and device patents for vaginal delivery, (ii) method-of-use patents tied to specific dosing regimens and indications, and (iii) country-by-country secondary patent thickets rather than single “core” patents. Competitive pressure is highest where products have short device/formulation life cycles and where FDA and EMA review pathways enable faster generic or hybrid entry. Patent expiry timing and Orange Book (or local reference lists) status are decisive at the subclass level, so market dynamics track each molecule and formulation rather than the ATC code alone.

Which antiinflammatory vaginal products drive ATC G02CC revenue and where is patent risk concentrated?

ATC G02CC is a therapeutic bucket for vaginal antiinflammatory products. In practice, the subclass market is shaped by individual active ingredients and fixed-dose combinations with vaginal dosage forms (creams, gels, suppositories/pessaries, and inserts). Patent risk concentrates where products rely on:

Vaginal formulation IP (polymeric systems, mucoadhesive excipients, emulsions, controlled-release matrices, particle engineering, preservative systems)
Vaginal administration device IP (applicator systems, dosing mechanics, insert geometries, compatibility of insert with formulation)
Dosing regimen IP (frequency, duration, step-down regimens, “after X weeks” schedules)
Indicator-constrained method patents (specific inflammatory conditions and patient subsets)

Featured snippet answer: Patent risk concentrates in countries where secondary patents (formulation/regimen/device) expire earlier than the primary composition-of-matter, enabling generic entry with design-around formulations and noninfringing dosing.

Typical product patterns within G02CC

Because G02CC is an ATC subclass, its composition is defined by therapeutic use and route, not by a single active. The most common commercial patterns in the broader vaginal antiinflammatory space include:

Corticosteroid vaginal formulations for vulvovaginal inflammatory disorders
Combination products where antiinflammatory effects are paired with antiinfective or antifungal components (often increasing formulation complexity and patent density)
Adjunct antiinflammatory agents where the therapeutic value is tied to local delivery and residence time

What patents protect vaginal antiinflammatory formulations in ATC G02CC? (composition, formulation, device, and regimen)

Featured snippet answer: The patent estate typically spans four layers: composition-of-matter (if the active is new), formulation (delivery vehicle and stability), device/applicator (how dose is administered), and method-of-use (dose schedule and indication).

Composition-of-matter patents: the minority driver inside old product sets

Where the active ingredient is mature, composition-of-matter patents may be expired or narrow. The enforceable leverage often comes from secondary IP.

Formulation patents: the core protection layer for vaginal delivery

Key formulation levers that commonly generate enforceable IP in vaginal products:

Mucoadhesive systems to extend residence time on vaginal mucosa
Controlled-release matrices (polymeric gels, sustained-release suppository bases)
Particle-size and dispersion for uniform drug distribution
Emulsion or thermoreversible gel platforms
Stability and preservative frameworks to maintain potency and tolerability

Device and applicator patents: common in semi-solid and insert dosing

Vaginal products frequently use applicators and inserts that can be protected:

Applicator geometry and dosing mechanics
Compatibility of applicator with gel viscosity ranges
Insert structural design to support consistent placement and dissolution

Method-of-use patents: regimen specificity

Method patents often track:

Start-to-finish regimen structure (e.g., induction then maintenance)
Frequency (once daily vs twice daily)
Duration thresholds and stop criteria
Indication language that ties use to specific inflammatory diagnoses

When do patents and exclusivity for G02CC vaginal antiinflammatory products lose exclusivity?

Featured snippet answer: Exclusivity usually falls in a staggered pattern. Even if a primary composition patent expires, formulation/device/method patents can maintain exclusivity-like market control through follow-on protection and infringement risk for generics.

How the timeline typically breaks down

Primary composition expiry (if applicable): earliest catalyst for generic/hybrid risk
Formulation patent expiry: delays generic entry unless design-around is successful
Device patent expiry: impacts ability to launch with “same delivery” compliance
Method-of-use expiry: limits labeling and can create safe-harbor design constraints

Practical market timing dynamic

Brands can tolerate “label erosion” if they defend method-of-use and keep competitive differentiation through formulation performance.
Generics may accept narrower labeling if they avoid patented regimen language.
Settlement agreements commonly trade timed market entry for noninfringement positions.

How many patents cover a typical ATC G02CC vaginal product, and which assignees hold the largest estates?

Featured snippet answer: Patent estates in this niche are usually product-specific and assignee-dependent; the largest estates tend to be held by originators and their reformulation subsidiaries, with multiple follow-on patents across formulation and device categories.

How to count “coverage” for competitive assessment

Patent coverage for a G02CC product is best assessed by counting:

Composition-of-matter patents (often 0-1 enforceable in mature products)
Formulation patents (commonly multiple)
Delivery/device patents (often multiple for applicator/insert systems)
Method-of-use patents (often multiple, especially if clinical programs support regimen language)
Process/manufacturing patents (relevant where solids handling, sterilization, and aseptic packaging processes are protected)

Assignee concentration dynamic

In practice, the assignee landscape clusters by:

Originator pharma holding the original product development file
Licensees controlling distribution and local regulatory submissions
Contract manufacturers with process patents (less frequent to be enforceable at market-entry scale unless claimed broadly)

What is the Orange Book status of ATC G02CC vaginal antiinflammatory products?

No complete Orange Book mapping by ATC code is reliably determinable from ATC alone. Orange Book listings are product-specific and depend on:

FDA-approved active ingredient(s)
Finished drug product(s)
Listed patents tied to those applications (NDA/BLA/505(b)(2) where applicable)

Featured snippet answer: Orange Book status must be evaluated per active and NDA label, because ATC G02CC spans multiple active ingredients and dosage forms that may have different regulatory families and listed-patent counts.

Which generic entry risks exist for ATC G02CC vaginal antiinflammatory products? (ANDA, 505(b)(2), and design-around)

Featured snippet answer: Entry risk rises when patents are concentrated in composition-of-matter and expire before formulation/device/method patents. Risk is lower where the brand’s formulation and regimen patents remain in-force, forcing generics into design-around either through different excipient systems, different release profiles, different applicators, or different dosing language.

Typical generic pathways and risk profiles

ANDA (generic): requires proof of bioequivalence and noninfringement or invalidity positions on listed patents (where Orange Book applies).
505(b)(2): often used for reformulated versions, potentially narrowing infringement but still implicating method/regimen protection depending on labeling.

Common design-around approaches

Change mucoadhesive polymer selection while matching release and tolerability
Reformulate to avoid protected particle dispersion or emulsifier systems
Reconfigure applicator to avoid device patent claims
Use a different dosing schedule that avoids method-of-use coverage, accepting labeling limitations

What patent litigation affects ATC G02CC vaginal antiinflammatory products? (Paragraph IV, injunctions, settlements)

Featured snippet answer: Litigation in this category tends to be settlement-driven, with Paragraph IV challenges in FDA-linked markets where listed patents exist. The most common levers are noninfringement on formulation/device claims and invalidity of secondary patents through obviousness-type arguments.

Litigation mechanics that matter

Claim construction around formulation composition ranges (polymer percentages, viscosity windows, release kinetics)
Device claim mapping (applicator mechanics and insert geometry)
Method-of-use labeling (regimen wording and implied use)
Design-around feasibility before launch dates

Settlement-driven entry windows

Settlement agreements in vaginal product classes often:

Set a launch date for generic entry
Include carve-outs for noninfringing formulations or changed labeling
Restrict launch design to avoid injunction-triggering trade dress or device mechanics

How does ATC G02CC compare with adjacent vaginal antiinfective/antiinflammatory classes in patent intensity and entry dynamics?

Featured snippet answer: Compared with vaginal antiinfectives (often pathogen- and spectrum-driven), G02CC antiinflammatory products frequently have higher formulation and device dependence because therapeutic effect is local, residence-time sensitive, and formulation-performance dependent.

Adjacent ATC subclasses and what they imply for patent strategy

Anti-infectives: often see more fixed composition repetition, but fewer “delivery convenience” patents if generic excipient choices are tolerant.
Combination products: increase patent density because multiple actives create more dependent formulation constraints and more room for inventing stability and compatibility systems.

Which formulation and delivery system patents matter most for noninfringing generic launches?

Featured snippet answer: For vaginal antiinflammatory products, the highest leverage noninfringement targets are formulation claims tied to:

specific mucoadhesive excipient combinations,
controlled-release profiles,
stability-preserving excipient systems,
and device-enabled dosing mechanics.

Practical claim categories to screen

For any given G02CC product:

Mucoadhesive polymer and concentration claims
Release rate or time-to-release claims
Emulsion/thermoreversible gel composition claims
Preservation and antimicrobial excipient claims
Insert/base geometry and dissolution behavior claims
Applicator dosing step claims
Dosing regimen claims in method-of-use patents

What manufacturing and IP barriers block competitors in G02CC vaginal products?

Featured snippet answer: The barrier is usually not manufacturing chemistry per se but maintaining the protected microstructure, viscosity and release characteristics, and device integration at commercial scale.

Barriers that can delay entry

Reproducing rheology and residence-time performance for bioequivalence
Achieving dissolution profiles that map to formulation claims
Ensuring stability through packaging and shelf-life constraints
Device-formulation integration (applicator compatibility with viscosity and flow)

Commercial outlook: which patent-expiry scenarios create the biggest revenue swings for ATC G02CC?

Featured snippet answer: Revenue swings cluster around three events:

expiry of formulation/device patents that define “the same product feel”
final adjudication or settlement that permits generic labeling and launch
exclusivity windows for 505(b)(2) reformulations that temporarily block straightforward ANDA switching

Scenario matrix

Scenario	Patent trigger	Generic leverage	Brand exposure
Early composition expiry, late formulation/device	Formulation/device remains	Partial design-around possible	Moderate-to-high risk
Broad method-of-use coverage	Regimen claims extend	Label restrictions reduce switch	High protection if branding keeps regimen wording
Device/applicator patent core	Delivery mechanics protected	Design-around possible but costly	Moderate protection if applicator is central to differentiation
Settlement with delayed launch	Injunction risk traded	Timed entry possible	Reduced near-term risk

Key Takeaways

ATC Class G02CC is governed less by the ATC code than by product-by-product patent estates spanning formulation, device/applicator, and method-of-use.
Secondary patents (formulation, device, regimen) typically drive the enforceability tail that delays generic entry even after earlier composition IP ends.
Competitive risk is highest where the brand’s enforceable claims are narrow enough for a generic to design around excipients, delivery systems, and labeling/regimen.
Where Orange Book-type listed patents exist in FDA-linked markets, litigation and settlements usually determine launch timing more than generic technical capability.
Market dynamics are best forecast by mapping each G02CC product’s patent expiry sequence and planned regulatory pathway (ANDA vs 505(b)(2)) to identify whether the generic can avoid formulation/device/method claim targets.

FAQs

What claim types should be prioritized when assessing noninfringement for vaginal antiinflammatory formulations?
How do settlements typically structure launch dates for vaginal semi-solid and insert products?
What formulation changes most often avoid infringement while preserving vaginal residence time?
How does labeling language around dosing frequency impact method-of-use infringement risk?
Which delivery device features are most frequently targeted in applicator and insert patent portfolios?

References

No sources cited.

Drugs in ATC Class G02CC

Drugs in ATC Class: G02CC - Antiinflammatory products for vaginal administration

Market Dynamics and Patent Landscape for ATC Class G02CC (Antiinflammatory Products for Vaginal Administration)